Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 5:3:104094.
doi: 10.1016/j.nsa.2024.104094. eCollection 2024.

Neurovascular coupling of striatal dopamine D2/3 receptor availability and perfusion using simultaneous PET/MR in humans

Christian N Schmitz  1   2   3   4 , Xenia M Hart  1   5 , Moritz Spangemacher  1   2   3   4 , Jana L Roth  1   3   4 , Ivana Lazarevic  1   3   4 , Gunilla Oberthür  6   3   4 , Karen A Büsing  7 , Robert Becker  6   3   4 , Paul Cumming  8   9 , Gerhard Gründer  1   3   4
Affiliations

Neurovascular coupling of striatal dopamine D2/3 receptor availability and perfusion using simultaneous PET/MR in humans

Christian N Schmitz et al. Neurosci Appl. .

Abstract

The midbrain dopamine system contributes to important neural functions in the basal ganglia, and is involved in aspects of pathological processes in schizophrenia. In preclinical and clinical studies, pharmacological blockade or stimulation of brain dopamine receptors alters cerebral perfusion, which is a surrogate marker of metabolic activity. However, there is scant documentation of this neurofunctional coupling in relation to individual differences in the dopamine system of healthy humans. We therefore tested the hypothesis that baseline dopamine D2/3 receptor availability predicts individual blood flow responses to challenge with a dopamine agonist. We used [18F]fallypride positron emission tomography (PET) imaging to quantify dopamine D2/3 receptor availability as binding potential (BPND) in nine healthy subjects. Using simultaneous perfusion-weighted functional magnetic resonance imaging (fMRI), we measured perfusion at baseline and after challenge with the dopamine agonist apomorphine. Results of this multimodal imaging study revealed a strong negative association between baseline D2/3 dopamine receptor availability and apomorphine-induced perfusion changes in the human basal ganglia. There was considerable intra-individual variation in the neurovascular response to the apomorphine challenge, which may call for further investigation of the dopaminergic regulation of cerebral perfusion in patients with schizophrenia. This study describes a novel paradigm for assessing dopamine sensitivity, facilitating an exploration of the dopamine supersensitivity hypothesis.

Keywords: Dopamine; Human; PET; Perfusion; fMRI; pcASL.

PubMed Disclaimer

Conflict of interest statement

No potential competing interests to report.

Figures

Fig. 1
Fig. 1
A) Experimental design: Representative time activity curves of the PET acquisition for the bilateral regions: putamen (Put), caudate nucleus (CN), thalamus, inferior temporal cortex (ITC) and cerebellum (Cer). The start of each time frame of the PET acquisition is denoted as tick on the horizontal axis. The time point of the administration of the dopamine agonist apomorphine is depicted as vertical dotted line. Periods of the perfusion weighted image acquisitions (ASL) are marked in dark grey. Inter-session pauses of PET-acquisition are marked in light grey, the signal of the inter-session pauses is based on linear interpolation. b) Representative parametric maps fused with a structural T1-weighted MR MNI152 NLIN 6th generation template (1), fusion parametric map of the dopamine receptor D2/3 binding potential combined with the structural T1-weighted MR MNI152 template (2) and fusion parametric map of cerebral blood flow combined with the structural T1-weighted MR MNI152 template (3).
Fig. 2
Fig. 2
Change in cerebrovascular blood flow (ΔrCBF) in the bilateral striatum upon administration of the dopamine D2/3R agonist apomorphine as a function of the mean [18F]FP BPND in the group of nine healthy participants.
See this image and copyright information in PMC

References

    1. Agbo F., Crass R.L., Chiu Y.Y., Chapel S., Galluppi G., Blum D., et al. Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease. Clin Transl Sci. 2021;14(4):1464–1475. - PMC - PubMed
    1. Alsop D.C., Detre J.A., Golay X., Gunther M., Hendrikse J., Hernandez-Garcia L., et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn. Reson. Med. 2015;73(1):102–116. - PMC - PubMed
    1. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. 1995;57:289–300. B.
    1. Bojesen K.B., Glenthøj B.Y., Sigvard A.K., Tangmose K., Raghava J.M., Ebdrup B.H., et al. Cerebral blood flow in striatum is increased by partial dopamine agonism in initially antipsychotic-naïve patients with psychosis. Psychol. Med. 2023;53(14):1–11. - PMC - PubMed
    1. Bruinsma T.J., Sarma V.V., Oh Y., Jang D.P., Chang S.Y., Worrell G.A., et al. The relationship between dopamine neurotransmitter dynamics and the blood-oxygen-level-dependent (BOLD) signal: a review of pharmacological functional magnetic resonance imaging. Front. Neurosci. 2018;12:238. - PMC - PubMed